Advertisement
Screener

AKEBIA THERAPEUTICS, INC. (AKBA) Debt Securities, Available-for-sale, Amortized Cost

1.9 / 5 stars · 34/88 Roast Me

AKEBIA THERAPEUTICS, INC. Debt Securities, Available-for-sale, Amortized Cost

AKEBIA THERAPEUTICS, INC. (AKBA) had Debt Securities, Available-for-sale, Amortized Cost of $0 as of 2021-09-30, per its 10-Q filed 2021-11-04.

Discontinued › Notes › Credit Losses

us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2022-03-01

  • 2021-09-30: Debt Securities, Available-for-sale, Amortized Cost $0.00.
  • 2021-06-30: Debt Securities, Available-for-sale, Amortized Cost $0.00.
  • 2021-03-31: Debt Securities, Available-for-sale, Amortized Cost $20.00M.
  • 2020-12-31: Debt Securities, Available-for-sale, Amortized Cost $39.98M.
Period endDebt Securities, Available-for-sale, Amortized Cost
2021-09-30$0.00
10-Q · filed 2021-11-04
2021-06-30$0.00
10-Q · filed 2021-08-05
2021-03-31$20.00M
10-Q · filed 2021-05-10
2020-12-31$39.98M
10-K · filed 2022-03-01
2020-09-30$99.96M
10-Q · filed 2020-11-05
2020-06-30$49.95M
10-Q · filed 2020-08-10
2019-12-31$245.00K
10-K · filed 2021-02-25
2019-09-30$22.72M
10-Q · filed 2019-11-12
2019-06-30$49.53M
10-Q · filed 2019-08-08
2019-03-31$105.33M
10-Q · filed 2019-05-09
2018-12-31$217.26M
10-K · filed 2020-03-12
2018-09-30$228.12M
10-Q · filed 2018-11-08
2018-06-30$239.06M
10-Q · filed 2018-08-08
2017-12-31$248.08M
10-K · filed 2019-03-26

Similar stocks

Stock NameCountryMarket CapPE Ratio
Lyell Immunopharma, Inc. (LYEL)United States$0.248B-1.32
Pyxis Oncology, Inc. (PYXS)United States$0.244B
Greenwich LifeSciences, Inc. (GLSI)United States$0.267B-15.02
Entrada Therapeutics, Inc. (TRDA)United States$0.243B-1.73
Cue Biopharma, Inc. (CUE)United States$0.243B-1.01
MACROGENICS INC (MGNX)United States$0.242B-20.11
Mereo BioPharma Group plc (MREO)$0.269B-9.41
Camp4 Therapeutics Corp (CAMP)United States$0.240B-2.12
Sionna Therapeutics, Inc. (SION)United States$0.236B-20.37
SIGA TECHNOLOGIES INC (SIGA)United States$0.234B-93.33